JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

13.51 2.5

Buy Sell

Overview

Share price change

24h

Current

Min

12.92

Max

13.51

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.989 49.8
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+50.38% upside

Market Stats
By TradingEconomics
Market Cap	2.3B
Previous open	11.01
Previous close	13.51

News Sentiment

By Acuity

50%

180 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 maj 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 maj 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 maj 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 maj 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 maj 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 maj 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 maj 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 maj 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 maj 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 maj 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 maj 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 maj 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 maj 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 maj 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 maj 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 maj 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 maj 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

50.38% upside

12 Months Forecast

Average 20 USD 50.38%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

180 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.